OncoMatch/Clinical Trials/NCT06057935
A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma
Official title: ICARuS II (Intraperitoneal Chemotherapy After cytoReductive Surgery): A Multicenter, Randomized Phase II Trial of Normothermic Intraperitoneal Chemotherapy and Intravenous Chemotherapy After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma
Is NCT06057935 recruiting? Yes, currently enrolling (Oct 2026). This Phase 2 trial studies multiple treatments including Pemetrexed and Cisplatin for malignant peritoneal mesothelioma.
Treatment: Pemetrexed · Cisplatin · Carboplatin — The purpose of this study is to find out whether intraperitoneal or intravenous chemotherapy given after cytoreductive surgery and HIPEC are effective treatments for people with malignant peritoneal mesothelioma. Outcomes will be compared by observing intraperitoneal versus intravenous treatments to analyze if one is better than the other.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Cancer type
Mesothelioma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: intraperitoneal chemotherapy
Subjects who have previously undergone intraperitoneal chemotherapy
Cannot have received: systemic chemotherapy for peritoneal mesothelioma
Subjects who have previously undergone ... systemic chemotherapy/immunotherapy for peritoneal mesothelioma
Cannot have received: immunotherapy for peritoneal mesothelioma
Subjects who have previously undergone ... systemic chemotherapy/immunotherapy for peritoneal mesothelioma
Cannot have received: platinum-based chemotherapy
Subjects who have previously received platinum-containing chemotherapy regimens
Lab requirements
Blood counts
ANC ≥ 1,500/µl; Platelets > 75,000/µl
Kidney function
creatinine < 1.5× ULN or calculated creatinine clearance of ≥50 ml/min
Liver function
bilirubin < 1.5 mg/dl (except in patients with Gilbert's syndrome, who must have total bilirubin < 3.0 mg/dL)
Hematology: ANC ≥ 1,500/µl. Platelets > 75,000/µl. Adequate renal function: creatinine < 1.5× ULN or calculated creatinine clearance of ≥50 ml/min. Adequate hepatic function: bilirubin < 1.5 mg/dl (except in patients with Gilbert's syndrome, who must have total bilirubin < 3.0 mg/dL).
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Chicago (Data Collection Only) · Chicago, Illinois
- University of Michigan (Data Collection Only) · Ann Arbor, Michigan
- Washington University (Data Collection Only) · St Louis, Missouri
- University of Nebraska (Data collection only) · Omaha, Nebraska
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) · Basking Ridge, New Jersey
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06057935 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior intraperitoneal chemotherapy, systemic chemotherapy for peritoneal mesothelioma, immunotherapy for peritoneal mesothelioma disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages